Showing papers on "Buprenorphine published in 1980"

Buprenorphine suppresses heroin use by heroin addicts

Abstract: Heroin-dependent men were given buprenorphine (a partial opiate agonist-antagonist) or a placebo under duoble-blind conditions on a clinical research ward where they could acquire heroin (21 to 40.5 milligrams per day, intravenously). Buprenorphine significantly (P less than .001) suppressed the self-administration of heroin over 10 days. Control subjects took between 93 and 100 percent of the available heroin. The effects of buprenorphine were dose-dependent; a dose of 8 milligrams per day reduced heroin use by 69 to 98 percent; a dose of 4 milligrams per day reduced heroin use by 45 percent. Termination of buprenorphie maintenance did not result in opiate withdrawal signs or symptoms. The subjects liked buprenorphine and indicated that it was preferable to methadone or naltrexone. Buprenorphine should be a safe and effective new pharmacotherapy for heroin dependence.

Clinical effects of buprenorphine during and after operation

Abstract: The analgesic, respiratory and hormonal effects of two doses of buprenorphine were studied during and after operation in 20 patients undergoing total hip replacement. The drug provided analgesia of long duration. The analgesic and hormonal effects of the drug were greater after i.m. thnn after i.v. administration. The postoperative analgesic requirement of women was less than that of men. The pharmacodynamic differences shown between the sexes and between the two routes of administration are discussed in relation to the pharmacokinerics of the drug.

Double‐blind, Multiple‐dose Comparison of Buprenorphine and Morphine in Postoperative Pain

Abstract: The analgesic profile and side-effects of buprenorphine 0.3 mg and morphine 10 mg intramuscularly were compared postoperatively in a double-blind, non-crossover, multiple-dose study. When the patient complained of moderate to severe postoperative pain after halothane-relaxant anesthesia for upper abdominal surgery, the first test dose of either drug was given. Subsequent similar doses of buprenorphine 0.3 mg or morphine 10 mg were given when required (maximum ten doses). The first dose of both drugs gave an equal decrease in pain intensity, suggesting a relative potency of 33:1 for both buprenorphine/morphine. A mean of 0.51 mg buprenorphine or 17 mg morphine had to be administered for satisfactory initial analgesia. Thereafter, the next analgesic dose was required a mean of 10.3 h after buprenorphine compared to 5.9 h after morphine (P less than 0.01). Significantly (P less than 0.01) fewer analgesic doses (mean 5.6) were needed in the buprenorphine group within the first 48 h postoperatively as compared to the morphine group (mean 7.3). A more pronounced mean decrease in the respiratory rate was observed after buprenorphine, but the mean minimum respiratory rates did not differ significantly from each other. Other effects of the two drugs on vital signs were similar. The incidence of other side-effects was fairly similar after both analgesics. The patients' subjective appraisal favoured buprenorphine.

Buprenorphine in postoperative pain: results in 7500 patients.

Abstract: Summary Buprenorphine, a partial opiate-receptor agonist with potent analgesic properties, was given to 7548 patients in the immediate postoperative period. Ninety per cent of patients had good or adequate pain relief for at least 4 hours; there were few adverse effects and the incidence of drug-associated respiratory depression was estimated at less than 1%. There were no other side-effects of clinical note.

A double-blind comparison between fentanyl and buprenorphine in analgesic-supplemented anaesthesia

Abstract: SUMMARY Buprenorphine 0.3 mg or featnnyl 0.125 mg i.v. were used to supplement nitrous oxide anaesthesia in a double-blind investigation of 40 parients undergoing major abdominal surgery. Initially both narcotics appeared to suppress tachycardia and increased arterial pressure in response to surgery, but 80% of the patients who received fentanyl eventually required a further supplement of halothane O.5%, whereas no patient who received buprnorphine required halothane Recovery from anaesthesia was similar in both groups, but the duration of analgesia after operation was significantly greater after buprenorphine than after fentanyl.

Biphasic dose response to buprenorphine in the rat tail flick assay: effect of naloxone pretreatment

Abstract: Buprenorphine demonstrates a well developed and reproducible biphasic dose-response curve in the rat radiant heat tail flick assay Prior administration of naloxone produces a shift of the total curve to the right and a result of this behaviour is that over a limited dose range, the antagonist potentiates rather than decreases the response due to buprenorphine Measurement of buprenorphine brain levels failed to demonstrate saturation of receptors over the dose range producing the biphasic response though saturation effects were observed at higher doses It is suggested that these data support the existence, in the whole animal, of two functionally related opiate receptor populations

The Monitored Release of Buprenorphine: Results in the Young

Abstract: Temgesic Injection (buprenorphine), apotent analgesic agent, was given to 240 patients under 18 years of age during a year ofmonitored release.All but four had the product for the managementofmoderate or severe pain in the immediate post-operative period. Analgesia was reported as adequate or good in 90% ofthese youngpatients when it was assessed2 and 4 hours after injection. There were no reports of side-effects commonly associated with strong analgesics and particularly antagonist-analgesics such as confusion, hallucination, blurred vision, dry mouth and lightheadedness. There were no serious respiratory or cardiovascular effects..The incidences ofother events did not differ from those recorded in the much larger adult populationof almost 8,000 patients. Buprenorphine is an effective analgesic suitable for use in the young post-operative patient.

[Comparison between the analgesic effects of buprenorphine and morphine in conscious man (author's transl)].

Abstract: Side-effects of increasing doses of morphine (0.100, 0.150, 0.200 mg/kg) and buprenorphine (0.0015, 0.003, 0.006 mg/kg), given intramuscularly, are clinically observed in conscient subjects suffering from intense pain in the facial or trigeminal nerves territory. Buprenorphine induces a drop in ventilation even with the lower doses, which persists for 120-180 minutes. This effect is more important after the injection of an equianalgesic dose of morphine. The same phenomenon is observed for the drop in heart rate and for the hypotension, which remained in all cases very slight. The central side-effects are of the same nature with buprenorphine and with morphine. On the whole this phenomenon appears with the same frequency with both drugs, especially for drowsiness and sleep, for nausea, vomiting and dizziness. Yet, the patient under buprenorphine becomes more frequently confused and agitated. Lastly, a state of euphoria can occur which might be feared to be related to a drug-addict activity of buprenorphine.